 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that TGTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

TG Therapeutics (TGTX, $12.49) RSI Indicator left the overbought zone on November 29, 2023

Rhumbline Advisers boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX  Free Report) by 5.6% in the second quarter, according to its most recent filing with the Securities and...

Rhumbline Advisers Has $4.71 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX  Get Free Report) was downgraded by equities research analysts at StockNews.com from a buy rating to a hold rating in a research report...

TG Therapeutics (NASDAQ:TGTX) Downgraded by StockNews.com

Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ETNEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the...

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

This price move could be a signal that TGTX may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

TG Therapeutics (TGTX, $12.82) price may drop as it broke higher Bollinger Band on Nov 20, 2023

TG Therapeutics (TGTX, $11.26) RSI Indicator left the overbought zone on November 15, 2023

TG Therapeutics, Inc. (NASDAQ:TGTX  Get Free Report) has been given a consensus rating of Moderate Buy by the eight ratings firms that are currently covering the firm, MarketBeat...

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts

Bank of New York Mellon Corp lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX  Free Report) by 25.7% in the 2nd quarter, according to its most recent Form 13F filing with the...

Bank of New York Mellon Corp Has $14.65 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics (TGTX, $10.14) RSI Indicator left the overbought zone on November 09, 2023

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Watchers	17,065
52-Wk Low	$6.46
52-Wk High	$35.67

Market Cap	$1.89B
Volume (M)	6.73M
52-Wk High	$35.67
52-Wk Low	$6.46

TGTX TG Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals